Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms
Peter Johansson(Linköping University), Björn Andréasson(NU Hospital Group), Robyn M. Scherber(Blueprint Medicines (United States)), Johanna Abelsson(NU Hospital Group), Jan Samuelsson(Karolinska University Hospital), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Gunnar Birgegård(Uppsala University Hospital)
Cited by 55
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k